Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday. The brokerage currently has a $30.00 price objective on the stock. Zacks Investment Research’s price target indicates a potential upside of 13.46% from the company’s previous close.
According to Zacks, “Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. “
Separately, JPMorgan Chase & Co. set a $26.00 price target on shares of Enanta Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, August 9th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the stock. Enanta Pharmaceuticals has an average rating of “Hold” and a consensus price target of $27.24.
Shares of Enanta Pharmaceuticals (NASDAQ:ENTA) traded up 1.11% during mid-day trading on Tuesday, hitting $26.44. The stock had a trading volume of 193,167 shares. The stock’s 50-day moving average is $23.58 and its 200 day moving average is $24.97. Enanta Pharmaceuticals has a 12 month low of $16.75 and a 12 month high of $41.77. The firm has a market cap of $503.29 million, a PE ratio of 17.49 and a beta of 0.58.
Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings results on Monday, August 8th. The company reported ($0.06) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.03. The firm had revenue of $14 million for the quarter, compared to analyst estimates of $13.07 million. Enanta Pharmaceuticals had a net margin of 32.59% and a return on equity of 11.31%. The business’s revenue for the quarter was up 20.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.13 EPS. Equities research analysts predict that Enanta Pharmaceuticals will post $1.02 earnings per share for the current fiscal year.
Hedge funds have recently made changes to their positions in the stock. Virginia Retirement System acquired a new position in Enanta Pharmaceuticals during the first quarter valued at approximately $540,000. Pacad Investment Ltd. increased its position in Enanta Pharmaceuticals by 15.3% in the first quarter. Pacad Investment Ltd. now owns 9,800 shares of the company’s stock valued at $288,000 after buying an additional 1,300 shares during the period. TIAA CREF Investment Management LLC increased its position in Enanta Pharmaceuticals by 53.2% in the first quarter. TIAA CREF Investment Management LLC now owns 88,848 shares of the company’s stock valued at $2,609,000 after buying an additional 30,840 shares during the period. Prudential Financial Inc. increased its position in Enanta Pharmaceuticals by 60.4% in the first quarter. Prudential Financial Inc. now owns 48,714 shares of the company’s stock valued at $1,431,000 after buying an additional 18,344 shares during the period. Finally, BlackRock Fund Advisors increased its position in Enanta Pharmaceuticals by 2.9% in the first quarter. BlackRock Fund Advisors now owns 1,184,007 shares of the company’s stock valued at $34,774,000 after buying an additional 33,777 shares during the period. 70.82% of the stock is currently owned by institutional investors.
Enanta Pharmaceuticals Company Profile
Enanta Pharmaceuticals Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create molecule drugs primarily for the treatment of viral infections and liver diseases. The Company is engaged in discovering and developing inhibitors designed for use against the hepatitis C virus (HCV), as well as compounds for non-alcoholic steatohepatitis (NASH) and primary biliary cirrhosis (PBC).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.